Cyclosporine prolongs delayed graft function in kidney transplantation: Are rabbit anti-human thymocyte globulins the answer?

Nephron - Clinical Practice

Volumn 101, Issue 2, 2005, Pages

  Cravedi, Paolo ^a,b,c   Codreanu, Igor ^b,d   Satta, Antonio ^a   Turturro, Maria ^b   Sghirlanzoni, MariaChiara ^a   Remuzzi, Giuseppe ^a,b   Ruggenenti, Piero ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d Republican Clinical Hospital   (Moldova)

Author keywords

Cyclosporine A; Delayed graft function; Rabbit anti human thymocyte globulin; Renal transplant

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE KIDNEY FAILURE; ADULT; ANURIA; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; FEMALE; GRAFT FAILURE; HEALTH CARE COST; HOSPITAL; HOSPITAL COST; HOSPITAL DISCHARGE; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; DELAYED GRAFT FUNCTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RABBITS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 23944469871     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086224     Document Type: Article

References (26)

1. Perico N, Cattaneo D, Sayegh MH, Remuzzi G: Delayed graft function in kidney transplantation. Lancet 2004;364:1814-1827.
2. Shoskes DA, Halloran PF: Delayed graft function in renal transplantation: Etiology, management and long-term significance. J Urol 1996;155:1831-1840.
3. Jacobs SC, Cho E, Foster C, Liao P, Bartlett ST: Laparoscopic donor nephrectomy: The University of Maryland 6-year experience. J Urol 2004;171:47-51.
4. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL: Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation 1997;63:968-974.
5. Mercus JWS, Hoitsma AJ, Koene RAP: Detrimental effect of acute renal failure on the survival of renal allografts: Influence of total ischaemia time and anastomosis time. Nephrol Dial Transplant 1991;6:881-886.
6. Organ Procurement Transplant Network, 2004: http://OPTN.org
7. Perico N, Ruggenenti P, Scalamogna M, Remuzzi G: Tackling the shortage of donor kidneys: How to use the best that we have. Am J Nephrol 2003;23:245-259.
8. Canafax DM, Torres A, Fryd DS, Heil JE, Strand MH, Ascher NL et al: The effects of delayed function on recipients of cadaver renal allografts. Transplantation 1986;41:177-181.
9. Sanfilippo F, Vaughn WK, Spees EK, Lucas BA: The detrimental effects of delayed graft function in cadaver donor renal transplantation. Transplantation 1984;38:643-648.
10. Shoskes DA, Shahed AR, Kim S: Delayed graft function. Influence on outcome and strategies for prevention. Urol Clin North Am 2001;28:721-732.
11. Giral-Classe M, Hourmant M, Cantarovich D, Dantal J, Blancho G, Daguin P et al: Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int 1998;54:972-978.
12. Gaber LW, Gaber AO, Hathaway DK, Vera SR, Shokouh-Amiri MH: Routine early biopsy of allografts with delayed graft function: correlation of histopathology and transplant outcome. Clin Transplant 1996;10:629-634.
13. Howard RJ, Pfaff WW, Brunson ME, et al: Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival. Transplant Proc 1993;25:884.
14. Johnson CP, Kuhn EM, Hariharan S, Hartz AJ, Roza AM, Adams MB: Pre-transplant identification of risk factors that adversely affect length of stay and charges for renal transplantation. Clin Transplant 1999;13:168-175.
15. Bia MJ, Tyler KA: Effect of cyclosporine on renal ischemic injury. Transplantation 1987;43:800-804.
16. Inman SR, Davis NA, Olson KM, Lukaszek VA, McKinley MR, Seminerio JL: Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury. Urology 2003;62:750-754.
17. Vincenti F, Grinyo J, Ramos E et al: Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant Proc 1999;31:1246-1248.
18. Morales JM, Wrammer L, Kreis H, Durand D, Campistol JM, Andres A et al: Sirolimus does not exhibit nephrotoxity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002;2:436-442.
19. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J et al: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71:1282-1287.
20. McTaggart RA, Gottlieb D, Brooks J, Bacchetti P, Roberts JP, Tomlavich S et al: Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003;3:416-423.
21. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS et al: Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2003;281:F693-F706.
22. Halloran PF, Hunsicker LG: Delayed graft function: State of art, November 10-11, 2000. Summit Meeting, Scottsdale, Ariz. Am J Transplant 2001;1:115-120.
23. Michael HJ, Francos GC Burke JF, Besarab A, Moritz M, Gillum D et al: A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation 1989;48:805-808.
24. Schnitzler MA, Woodward RS, Lowell JA, Amir L, Schroeder TJ, Singer GG et al: Economics of the antithymocyte globulins Thymoglobulin and Atgam in the treatment of acute renal transplant rejection. Pharmacoeconomics 2000;17:287-293.
25. Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G: Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Clin Transplant 1996;10:550-555.
26. Sollinger H, Kaplan B, Pescovitz MD, et al: Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001;72:1915-1919.